Hepatitis B (HBV) is one of the most common viral infections of the liver worldwide. There are more than two billion people that have been infected, four million acute cases per year, and one million deaths per year. Out of those, 350–400 million are chronic carriers, and 25% of carriers die from chronic hepatitis, cirrhosis, or liver cancer.
KeywordsHepatitis B Hepatitis B reactivation Cirrhosis Screening Prophylactic treatment
The authors of this manuscript have no conflicts of interest to disclose.
- 1.CDC guidelines on HBV. https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm#treatment
- 2.Huang H, Li XY, Li HR, et al. Preventing hepatitis B reactivation in HBsAg-positive patients with untreated diffuse large B-cell lymphoma with R-CHOP chemotherapy: a prospective study to compare entecavir and lamivudine. J Clin Oncol. 2013;31:8503–3.Google Scholar
- 5.Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, AGA Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015 Jan;148(1):215–9.CrossRefGoogle Scholar